Ethnic differences in response to pharmaceuticals across Europe

  • Marisa Papaluca
Part of the CMR Workshop Series book series (CMRW)


  1. 1

    Ethnic variations exist across Europe, and have to be taken into due consideration, but the European regulatory approach enables each Member State to accept all available clinical data for evaluation, including that derived from different European, and even non-European, regions.

  2. 2

    A project is underway in Europe to compare the clinical safety of some medicinal products evaluated through the Concertation Procedure by assessing data on adverse drug reactions, observed during clinical trials and post-marketing, in each Member State.

  3. 3

    Preliminary results indicate that the qualitative profile of the detected serious ADRs does not show major differences across the European regions. This suggests that the existing ethnic differences have not had a direct impact on the detection of serious ADRs.



Member State Ethnic Difference Medicinal Product Spontaneous Reporting System Ethnic Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Papaluca M (1994). Patient exposure in Europe to medicinal products evaluated according to the CPMP Concertation Procedures. In: Fracchia GN (ed.) European Medicines Research: Perspectives in Pharmacotoxicology and Pharmacovigilance. EC-IOS Press. (in press 1994).Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1994

Authors and Affiliations

  • Marisa Papaluca

There are no affiliations available

Personalised recommendations